GlassScriptPhysician profile
Harini Balu
NPI 1851362701
$2,638.20
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $497 · 2021: $477 · 2022: $515 · 2023: $246 · 2024: $219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $464.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,224.64 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Abbvie INC. | $281.57 | 2021-2023 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $277.30 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Allergan, INC. | $173.96 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.30 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.77 | 2022-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $63.56 | 2019 | |
| Lundbeck LLC | $56.60 | 2022-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $54.83 | 2024 | Ingrezza |
| Indivior INC. | $47.53 | 2024 | Perseris |
| Eisai INC. | $45.38 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $38.24 | 2019-2023 | Uzedy |
| Noven Therapeutics, LLC | $37.84 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $29.26 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $13.42 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harini Balu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.